Trastuzumab (herceptin) and HER2-positive breast cancer

被引：8
|
作者：
Murray, S
机构：
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2006年 / 174卷 / 01期
关键词：
D O I：
10.1503/cmaj.051452
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：36 / 37
页数：2
相关论文
共 50 条
  • [1] Her2-positive breast cancer: Herceptin and beyond
    Dean-Colomb, Windy
    Esteva, Francisco J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2806 - 2812
  • [2] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    [J]. BMC CANCER, 2018, 18
  • [3] Pneumocystis jirovecii Pneumonia in a Patient with HER2-Positive Breast Cancer Treated with Trastuzumab (Herceptin)
    Van der Putten, S.
    Blazkova, S.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S240 - S241
  • [4] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    [J]. BMC Cancer, 18
  • [5] Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
    Ewer, M. S.
    Perez, E. A.
    Baselga, J.
    Bell, R.
    Brutsaert, D.
    Marty, M.
    Pienkowski, T.
    Suter, T. M.
    [J]. BREAST, 2007, 16 : S63 - S63
  • [6] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [7] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [8] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    [J]. LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [9] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [10] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
12345